Show:
Disease State
Cabo/METEOR
Sunitinib/Sorafenib
Everolimus
Pazopanib/Axitinib
100
RCC is the ___________ most common GU malignancy
What is third
100
Cabozantinib dose on the Drug/Drug Interaction study
What is 140 mg
100
Sunitinib's label carries a balck box warning for
What is hepatotoxicity
100
The RCC indication for AFINITOR
What is for the treatment of adults with advanced RCC after failure of treatment with sunitinib or sorafenib
100
The primary endpoint of the AXIS trial
What is PFS
200
RCC occurs most often in men of this age range
What is 50-70 years of age
200
The primary endpoint of the METEOR study
What is PFS
200
The dose and schedule of Nexavar for RCC patients
What is 400 mg BID without food
200
The RCC dose and schedule of everolimus
What is 10 mg qd with or without food
200
VOTRIENT carries this Black Box warning
What is hepatotoxicity
300
The percentage of renal cell carcinomas that is of clear cell histology
What is 75%
300
The PFS in the RCC cohort of the Drug/Drug Interaction study
What is 14.7 months
300
The dose and schedule of sunitinib for RCC patients
What is 50 mg qd with or without food, 4 weeks on treatment followed by 2 weeks off
300
The primary endpoint for the RECORD-1 trial
What is PFS
300
The dose and schedule for pazopanib
What is 800 mg qd without food
400
The components of the classic triad RCC presentation
What are flank pain, hematuria and presence of a flank mass
400
The number of patients enrolled on the RCC cohort of the Drug/Drug Interaction study
What is 25
400
The sunitinib package insert instructs to monitor LFTs
What is before initiation of treatment, during each cycle and as clinically indicated
400
The central radiology review PFS for RECORD-1
What is 4.9 months
400
Patients with baseline moderate hepatic impairment should receive this dose of VOTRIENT
What is 200 mg
500
The VHL gene is located on chromosome
What is 3p25
500
The maximum number of prior therapies allowed on the METEOR trial
What is no maximum
500
In Motzer's update to the phase 3 Sunitinib vs IFN trial, the updated ORR was __________ and the median OS was __________
What is 47% and 26.4 months
500
This warning and precaution is a class effect of rapamycin derivatives
What is non-infectious pneumonitis
500
The two most common adverse events leading to discontinuation in the Axitinib group of the phase 3 trial
What are fatigue and TIA